Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates

Core Insights - Harmony Biosciences reported quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share, but showing an increase from $0.79 per share a year ago, resulting in an earnings surprise of -5.43% [1] - The company posted revenues of $239.46 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.59% and up from $186.04 million year-over-year [2] - Harmony Biosciences shares have declined approximately 14.8% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $239.18 million, and for the current fiscal year, it is $3.23 on revenues of $864.24 million [7] - The estimate revisions trend for Harmony Biosciences was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Harmony Biosciences belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]